GlassScriptPhysician profile
Erin K Wiesner
NPI 1639493372
$3,219.61
in general payments reported to CMS, 2019-2025
19 companies · $1,892 in 2025
The $1,892 reported for 2025 was more than what 92% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,328 · 2025: $1,892.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,682 · Education: $538.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,681.66 |
| Education | $537.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $659.69 | 2024-2025 | Darzalex, Tecvayli, Talvey |
| Gilead Sciences, INC. | $524.46 | 2024-2025 | Trodelvy |
| Daiichi Sankyo INC. | $508.72 | 2024-2025 | Enhertu |
| Pfizer INC. | $273.91 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $254.81 | 2024-2025 | Enhertu, Imfinzi, Tagrisso |
| Merck Sharp & Dohme LLC | $218.27 | 2024-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Regeneron Healthcare Solutions, INC. | $197.35 | 2024-2025 | Libtayo, Lynozyfic |
| Novartis Pharmaceuticals Corporation | $170.53 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $106.38 | 2024-2025 | Iclusig |
| Genentech USA, INC. | $68.37 | 2024 | Ocrevus Zunovo, Venclexta, Actemra |
| Beigene USA, INC. | $46.48 | 2024-2025 | Tevimbra |
| Emd Serono, INC. | $41.53 | 2025 | |
| Tersera Therapeutics LLC | $30.47 | 2024 | Zoladex |
| Glaxosmithkline, LLC. | $24.08 | 2025 | Ojjaara |
| Eisai INC. | $22.75 | 2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $20.93 | 2025 | |
| Genmab U.S., INC. | $17.15 | 2025 | Tivdak |
| Astellas Pharma US INC | $16.94 | 2025 | Vyloy |
| Taiho Oncology, INC. | $16.79 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Wiesner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.